Approved in 2019, Risankizumab is the third FDA-approved inhibitor of the IL-23 p19 subunit for treating moderate-to-severe plaque psoriasis in adults, demonstrating a favorable safety and tolerability profile (202). The gene discussed is IL23A; the disease is psoriasis vulgaris.